Autoinsertion of soluble oligomers of Alzheimer's Aβ(1-42) peptide into cholesterol-containing membranes is accompanied by relocation of the sterol towards the bilayer surface

BMC Structural Biology

Volumn 6, Issue , 2006, Pages

  Ashley, Richard H ^a   Harroun, Thad A ^b,c,f   Hauss, Thomas ^d   Breen, Kieran C ^e,g   Bradshaw, Jeremy P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b CANADIAN NUCLEAR LABORATORIES   (Canada)

^c HAHN MEITNER INSTITUT   (Germany)

^d DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f BROCK UNIVERSITY   (Canada)

^g Institute of Neurology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DEUTERIUM; LAURDAN; MEMBRANE LIPID; OLIGOMER; PHOSPHATIDYLCHOLINE;

ALZHEIMER DISEASE; ARTICLE; BILAYER MEMBRANE; CHOLESTEROL BLOOD LEVEL; HUMAN; NERVE CELL MEMBRANE; NEUTRON DIFFRACTION; NONHUMAN;

AMYLOID BETA-PEPTIDES; BIOLOGICAL TRANSPORT; CHOLESTEROL; HUMANS; LIPID BILAYERS; NEUTRON DIFFRACTION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, QUATERNARY; SOLUBILITY; WATER;

EID: 33751313597     PISSN: 14726807     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-6-21     Document Type: Article

References (45)

1. Selkoe DJ: Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 2004, 6:1054-1061.
2. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498.
4. Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL: Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001, 79:595-605.
5. Lin H, Bhatia R, Lal R: Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 2001, 15:2433-2444.
6. Bitan G, Vollers SS, Teplow DB: Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003, 278:34882-34889.
7. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG: Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279:46363-46366.
8. Arispe N, Rojas E, Pollard HB: Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A 1993, 90:567-571.
9. Yip CM, McLaurin J: Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys J 2001, 80:1359-1371.
10. Arispe N, Doh M: Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J 2002, 16:1526-1536.
11. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
12. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003, 6:345-351.
13. Micelli S, Meleleo D, Picciarelli V, Gallucci E: Effect of sterols on beta-amyloid peptide (AbetaP 1-40) channel formation and their properties in planar lipid membranes. Biophys J 2004, 86:2231-2237.
14. Brockman H: Lipid monolayers: why use half a membrane to characterize protein-membrane interactions? Curr Opin Struct Biol 1999, 9:438-443.
15. Maget-Dana R: The monolayer technique: a potent tool for studying the interfacial properties of antimicrobial and membrane-lytic peptides and their interactions with lipid membranes. Biochim Biophys Acta 1999, 1462:109-140.
16. Harroun TA, Bradshaw JP, Ashley RH: Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett 2001, 507:200-204.
17. Gordeliy VI, Chernov NI: Accuracy of determination of position and width of molecular groups in biological and lipid membranes via neutron diffraction. Acta Crystallogr D Biol Crystallogr 1997, 53:377-384.
18. Balali-Mood K, Ashley RH, Hauss T, Bradshaw JP: Neutron diffraction reveals sequence-specific membrane insertion of prefibrillar islet amyloid polypeptide and inhibition by rifampicin. FEBS Lett 2005, 579:1143-1148.
19. Parasassi T, De Stasio G, Ravagnan G, Rusch RM, Gratton E: Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of laurdan fluorescence. Biophys J 1991, 60:179-189.
20. Harris FM, Best KB, Bell JD: Use of laurdan fluorescence intensity and polarization to distinguish between changes in membrane fluidity and phospholipid order. Biochim Biophys Acta 2002, 1565:123-128.
21. Worthman LA, Nag K, Davis PJ, Keough KM: Cholesterol in condensed and fluid phosphatidylcholine monolayers studied by epifluorescence microscopy. Biophys J 1997, 72:2569-2580.
22. Mason RP, Estermyer JD, Kelly JF, Mason PE: Alzheimer's disease amyloid beta peptide 25-35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis. Biochem Biophys Res Commun 1996, 222:78-82.
23. Dante S, Hauss T, Dencher NA: Insertion of externally administered amyloid beta peptide 25-35 and perturbation of lipid bilayers. Biochemistry 2003, 42:13667-13672.
24. Terzi E, Holzemann G, Seelig J: Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Biochemistry 1997, 36:14845-14852.
25. Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, Picone D: Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem 2002, 269:5642-5648.
26. Reyes MC, Ulises AA, Brochon JC: Liquid-crystalline phases of cholesterol/lipid bilayers as revealed by the fluorescence of trans-parinaric acid. Biophys J 1995, 68:978-987.
27. Harroun TA, Katsaras J, Wassall SR: Cholesterol hydroxyl group is found to reside in the center of a polyunsaturated lipid membrane. Biochemistry 2006, 45:1227-1233.
28. Kremer JJ, Sklansky DJ, Murphy RM: Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 2001, 40:8563-8571.
29. Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM: Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 2000, 39:10309-10318.
30. Michikawa M, Gong JS, Fan QW, Sawamura N, Yanagisawa K: A novel action of Alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci 2001, 21:7226-7235.
31. Maxfield FR, Tabas I: Role of cholesterol and lipid organization in disease. Nature 2005, 438:612-621.
32. Burger K, Gimpl G, Fahrenholz F: Regulation of receptor function by cholesterol. Cell Mol Life Sci 2000, 57:1577-1592.
33. Incardona JP, Eaton S: Cholesterol in signal transduction. Curr Opin Cell Biol 2000, 12:193-203.
34. Razani B, Woodman SE, Lisanti MP: Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002, 54:431-467.
35. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE: Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996, 271:4077-4081.
36. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ: The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
37. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo . Nature 2002, 416:535-539.
38. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ: Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006, 572:477-492.
39. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
40. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL: Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004, 24:10191-10200.
41. Ledesma MD, Dotti CG: Amyloid excess in Alzheimer's disease: What is cholesterol to be blamed for? FEBS Lett 2006, 580:5525-32.
42. Roth GS, Joseph JA, Mason RP: Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 1995, 18:203-206.
43. Yip CM, Elton EA, Darabie AA, Morrison MR, McLaurin J: Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. J Mol Biol 2001, 311:723-734.
44. Darkes MJ, Bradshaw JP: Real-time swelling-series method improves the accuracy of lamellar neutron-diffraction data. Acta Crystallogr D Biol Crystallogr 2000, 56:48-54.
45. Hristova K, White SH: Determination of the hydrocarbon core structure of fluid dioleoylphosphocholine (DOPC) bilayers by X-ray diffraction using specific bromination of the double-bonds: effect of hydration. Biophys J 1998, 74:2419-2433.